Literature DB >> 24726367

Mnk2 alternative splicing modulates the p38-MAPK pathway and impacts Ras-induced transformation.

Avraham Maimon1, Maxim Mogilevsky1, Asaf Shilo1, Regina Golan-Gerstl1, Akram Obiedat1, Vered Ben-Hur1, Ilana Lebenthal-Loinger1, Ilan Stein2, Reuven Reich3, Jonah Beenstock4, Eldar Zehorai5, Claus L Andersen6, Kasper Thorsen6, Torben F Ørntoft6, Roger J Davis7, Ben Davidson8, David Mu9, Rotem Karni10.   

Abstract

The kinase Mnk2 is a substrate of the MAPK pathway and phosphorylates the translation initiation factor eIF4E. In humans, MKNK2, the gene encoding for Mnk2, is alternatively spliced yielding two splicing isoforms with differing last exons: Mnk2a, which contains a MAPK-binding domain, and Mnk2b, which lacks it. We found that the Mnk2a isoform is downregulated in breast, lung, and colon tumors and is tumor suppressive. Mnk2a directly interacts with, phosphorylates, activates, and translocates p38α-MAPK into the nucleus, leading to activation of its target genes, increasing cell death and suppression of Ras-induced transformation. Alternatively, Mnk2b is pro-oncogenic and does not activate p38-MAPK, while still enhancing eIF4E phosphorylation. We further show that Mnk2a colocalization with p38α-MAPK in the nucleus is both required and sufficient for its tumor-suppressive activity. Thus, Mnk2a downregulation by alternative splicing is a tumor suppressor mechanism that is lost in some breast, lung, and colon tumors.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24726367     DOI: 10.1016/j.celrep.2014.03.041

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  47 in total

1.  Ras-Erk signaling induces phosphorylation of human TLE1 and downregulates its repressor function.

Authors:  T Zahavi; A Maimon; T Kushnir; R Lange; E Berger; D Kornspan; R Grossman; S Anzi; E Shaulian; R Karni; H Nechushtan; Z Paroush
Journal:  Oncogene       Date:  2017-02-13       Impact factor: 9.867

2.  Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer.

Authors:  Rozita Bagheri-Yarmand; Krishna M Sinha; Ling Li; Yue Lu; Gilbert J Cote; Steven I Sherman; Robert F Gagel
Journal:  Mol Cancer Res       Date:  2018-12-14       Impact factor: 5.852

Review 3.  The role of RNA alternative splicing in regulating cancer metabolism.

Authors:  Itamar Kozlovski; Zahava Siegfried; Adi Amar-Schwartz; Rotem Karni
Journal:  Hum Genet       Date:  2017-04-20       Impact factor: 4.132

4.  Novel alternatively spliced isoforms of MEF2A and their mRNA expression patterns in pigs.

Authors:  Xiao Hong Guo; Qi Zhang; Meng Li; Peng Fei Gao; Guo Qing Cao; Zhi Min Cheng; Ning Fang Zhang; Bao Yu Le; Jian Feng Liu; Xiao Jun Liu; Bu Gao Li
Journal:  J Genet       Date:  2018-09       Impact factor: 1.166

Review 5.  The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression.

Authors:  Asaf Shilo; Zahava Siegfried; Rotem Karni
Journal:  Mol Cell Oncol       Date:  2014-12-01

6.  Aberrant RNA Splicing in Cancer.

Authors:  Luisa Escobar-Hoyos; Katherine Knorr; Omar Abdel-Wahab
Journal:  Annu Rev Cancer Biol       Date:  2018-11-28

7.  Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis.

Authors:  Jianling Xie; Kaikai Shen; Ashley T Jones; Jian Yang; Andrew R Tee; Ming Hong Shen; Mengyuan Yu; Swati Irani; Derick Wong; James E Merrett; Roman V Lenchine; Stuart De Poi; Kirk B Jensen; Paul J Trim; Marten F Snel; Makoto Kamei; Sally Kim Martin; Stephen Fitter; Shuye Tian; Xuemin Wang; Lisa M Butler; Andrew C W Zannettino; Christopher G Proud
Journal:  Cell Mol Life Sci       Date:  2020-03-13       Impact factor: 9.261

Review 8.  Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

Authors:  Laura M Urbanski; Nathan Leclair; Olga Anczuków
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-04-25       Impact factor: 9.957

Review 9.  Carcinogenesis and Reactive Oxygen Species Signaling: Interaction of the NADPH Oxidase NOX1-5 and Superoxide Dismutase 1-3 Signal Transduction Pathways.

Authors:  Alessia Parascandolo; Mikko O Laukkanen
Journal:  Antioxid Redox Signal       Date:  2018-11-22       Impact factor: 8.401

Review 10.  Emerging functions of SRSF1, splicing factor and oncoprotein, in RNA metabolism and cancer.

Authors:  Shipra Das; Adrian R Krainer
Journal:  Mol Cancer Res       Date:  2014-05-07       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.